AYTU BioPharma
AYTU
38 hedge funds and large institutions have $8.25M invested in AYTU BioPharma in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 2 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
3% more funds holding
Funds holding: 37 → 38 (+1)
0.63% less ownership
Funds ownership: 36.37% → 35.74% (-0.63%)
23% less capital invested
Capital invested by funds: $10.7M → $8.25M (-$2.41M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$285K |
| 2 |
CAM
Crown Advisors Management
Larkspur,
California
|
+$130K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$29.7K |
| 4 |
Renaissance Technologies
New York
|
+$26.2K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$20.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$483K |
| 2 |
PAP
Persistent Asset Partners
Hong Kong
|
-$130K |
| 3 |
Two Sigma Investments
New York
|
-$39.3K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$9.76K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$392 |
AYTU Hedge Fund Activity: Q2 2026 in Review
38 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q2 2026, worth a combined $8.25M — down 23% from $10.7M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new AYTU positions and 2 closed out — a net gain of 1 holder — while 11 added to existing stakes and 5 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $285K. The largest seller was Diadema Partners, cutting an estimated $483K.
- 38 institutional investors held AYTU BioPharma (AYTU) as of Q2 2026, up from 37 in Q1 2026.
- Funds reported $8.25M of AYTU BioPharma stock for Q2 2026, down 23% quarter-over-quarter.
- 3 funds opened new AYTU BioPharma positions in Q2 2026 and 2 closed out, a net change of +1 holder.
- The largest AYTU BioPharma buyer in Q2 2026 was Stonepine Capital Management, an estimated $285K added.
- The largest AYTU BioPharma seller in Q2 2026 was Diadema Partners, an estimated $483K sold.
Based on aggregated 13F filings for Q2 2026.